Organic Process Research & Development
ARTICLE
123.4, 115.8, 110.9, 63.6, 61.1, 56.3, 52.3, 50.7, 45.6, 36.9, 26.0,
25.1; 13C NMR (CDCl3, 100 MHz): δ 164.2, 161.3, 129.8, 122.5,
122.4, 116.3, 110.7, 66.3, 60.5, 58.9, 54.4, 53.8, 48.4, 39.2, 29.1,
26.9. Analysis of the spectroscopic data matched reported data.7
(9) Cyclic secondary amines are known to undergo alkylation with
methylene chloride, see: Mills, J. E.; Maryanoff, C. A.; McComsey, D. F.;
Stanzione, R. C.; Scott, L. J. Org. Chem. 1987, 52, 1857.
(10) Compound 3 may be isolated as a solid but is very low melting
(∼35 °C) and is likely a sensitizer or irritant. For these reasons we often
elected to prepare 3 just prior to its use in a coupling and to store it
temporarily as a solution to avoid handling of this material.
(11) Parikh, J. R.; Doering, W. v. E. J. Am. Chem. Soc. 1967, 89, 5505.
(12) To remove boron from the sodium borohydride reduction, 4
was treated with anhydrous HCl in methanol, distilled to a low volume,
and crystallized as the HCl salt. This operation reduced the boron levels
from ∼40,000 ppm down to below 20 ppm.
’ AUTHOR INFORMATION
Corresponding Author
*robert.a.singer@pfizer.com.
’ ACKNOWLEDGMENT
We thank Frank Urban for providing helpful insight to our
process research and development. We thank John Salisbury for
development of HPLC analytical methods. We thank the tech-
nicians of the Pilot Plant (Groton and Sandwich) and Kilo Lab
for their help in the scale up work. We acknowledge PCAS
(France) for the preparation of 26a on 40-kg scale.
(13) In our hands 3 does not appear to undergo oxidative insertion
by Pd readily. One test examined the coupling of 3 with phenyl boronic
acid. Even using this outstanding coupling partner failed to give more
than trace product using electron-rich ligands such as Xphos.
(14) For reviews on fluoride-promoted couplings, see: (a) Clark,
J. H. Chem. Rev. 1980, 80, 429. (b) Yakobson, G. G.; Akhmetova, N. E.
Synthesis 1983, 169. (c) Fringuelli, F.; Lanari, D.; Pizzo, F.; Vaccaro, L.
Curr. Org. Synth. 2009, 6, 203.
(15) Senanayake, C. H.; Hong, Y.; Xiang, T.; Wilkinson, H. S.;
Bakale, R. P.; Jurgens, A. R.; Pippert, M. F.; Butler, H. T.; Wald, S. A.
Tetrahedron Lett. 1999, 40, 6875.
(16) Carpino, L. A.; Sau, A. J. Chem. Soc., Chem. Commun. 1979, 514.
(17) For reports of the preparation of 21 and 22, see: (a) Leeming,
P.; Fronczek, F. R.; Ager, D. J.; Laneman, S. A. Top. Catal. 2000, 13, 175.
(b) Hubbs, J. C. U.S. Patent 5,144,073 A, 1992; (c) Toshihisa, K.;
Tadashi, T. Eur. Pat. Appl. EP 493812, 1992.
(18) The process began with esterification of L-aspartic acid and
coupling with BOC-glycine using CDI followed by deprotection under
acidic conditions and cyclization with neutralization using triethylamine.
It was later realized that the deprotection of the BOC group with MsOH
could lead to some epimerization of the stereocenter, depending on the
temperature control of the MsOH addition as well as the total stir time at
elevated temperature prior to adding triethylamine for cyclization. Use
of TFA or a milder acid than MsOH resulted in no epimerization.
(19) The vendor had concerns of fluoride etching the glass-lined
vessel and would require the use of a steel or Hastelloy vessel which was
not as readily available for the scale up.
’ REFERENCES
(1) The bicyclic piperazine motif has been used in various families of
pharmaceutical targets, see for example: (a) Salama, I.; Schlotter, K.; Utz,
W.; Hubner, H.; Gmeiner, P.; Boeckler, F. Bioorg. Med. Chem. 2006,
14, 5898. (b) Peng, H.; et al. J. Med. Chem. 2004, 47, 6218. (c) Sanner,
M. A.; et al. Bioorg. Med. Chem. Lett. 1998, 8, 725. (d) Bright, G. M.;
Desai, K. A. U.S. Patent 5,122,525, 1992; Chem. Abstr. 1991, 114, 81886;
(e) Saleh, M. A.; Compernolle, F.; Toppet, S.; Hoornaert, G. J. Tetra-
hedron 1994, 50, 1811. (f) Saleh, M. A.; Compernolle, F.; Van den
Braden, S.; De Buysser, W.; Hoornaert, G. J. Org. Chem. 1993, 58, 690.
(g) Compernolle, F.; Saleh, M. A.; Toppet, S.; Hoornaert, G. J. Org.
Chem. 1991, 56, 5192.
(2) The Pd-catalyzed amination has been highly developed, see: (a)
Surry, D. S.; Buchwald, S. L. Angew. Chem., Int. Ed. 2008, 47, 6338.
(b) Schlummer, B.; Scholz, U. Adv. Synth. Catal. 2004, 346, 1599.
(c) Hartwig, J. F.; Shekar, S.; Shen, Q.; Barrios-Landeros, F. In The
Chemistry of Anilines; Rappoport, Z., Ed.; Wiley: New York, 2007; p 455.
(d) Hartwig, J. F. In Modern Amination Methods; Ricci, A., Ed.;
Wiley-VCH: Weinheim, 2000; p 195.
(20) The slow dosing of the benzoic anhydride ensures that no more
than about 3% of bis-benzoylated amide side product forms. Adding the
benzoic anhydride over 1 h resulted in ∼7% or more of the bis-
benzoylated amide forming.
(21) Aside from the phosphate, we had prepared the mesylate,
chloride, and tosylate derivatives of 24; however, none of these cyclized
as readily as the phosphate.
(22) In addition to controlling the addition of THF to LHMDS and
25, it is important to maintain a lower temperature during the addition of
the THF when cyclization occurs.
(23) Vitride is also sold as Red-Al, which is a 65 wt % solution of
bis(2-methoxyethoxy)aluminum hydride in toluene.
(24) While 27 is commercially available, we typically prepared this
building block as follows: methyl salicylate was treated with hydro-
xylamine hydrochloride in aqueous base to obtain a hydroxamic acid
adduct which is crystallized upon treatment with aqueous HCl. This
intermediate is cyclized to 27 by slow addition of CDI in THF/
acetonitrile with heating and is crystallized from water/acetonitrile by
addition of aqueous HCl.
(25) The addition of phosphoric acid to POCl3 for improving the
efficiency of the conversion to the chloride has been reported
previously, see: Andersen, K.; Begtrup, M. Acta Chem. Scand. 1992, 46, 1130.
(26) At higher temperatures (100À120 °C) chlorination of the
benzisoxazole ring occurred, and these side products were found to be
difficult to purge downstream in the process.
(3) Electron-deficient aryl halides are more susceptible to undergo
oxidative addition and SNAr. Many heterocycles are intrinsically acti-
vated to these pathways as well, see: Joule, J. A.; Mills, K.; Smith, G. F.
Heterocyclic Chemistry, 3rd ed.; Chapman and Hall: New York, 1995.
(4) Some heterocyclic substrates are more challenging to optimize in
cross-coupling approaches due to inhibition of the Pd catalyst from the
substrate or product. A number of reports have focused on this
challenging class of substrates, see: Hartwig, J. F. J. Am. Chem. Soc.
2008, 130, 6586. Anderson, K. W.; Tundel, R. E.; Ikawa, T.; Altman,
R. A.; Buchwald, S. L. Angew. Chem., Int. Ed. 2006, 45, 6523. Charles,
M. D.; Schultz, P.; Buchwald, S. L. Org. Lett. 2005, 7, 3965. Yin, J. J.;
Zhao, M. M.; Huffman, M. A.; McNamara, J. M. Org. Lett. 2002, 4, 3481.
Shen, Q.; Shekhar, S.; Stambuli, J. P.; Hartwig, J. F. Angew. Chem., Int. Ed.
2005, 44, 1371. Shen, Q.; Ogata, T.; Hooper, M. W.; Utsunomiya, M.;
Hartwig, J. F. J. Org. Chem. 2003, 68, 2861. Wolfe, J. P.; Tomori, H.;
Sadighi, J. P.; Yin, J.; Buchwald, S. L. J. Org. Chem. 2000, 65, 1158.
Wagaw, S.; Buchwald, S. L. J. Org. Chem. 1996, 61, 7240.
(5) Aryl chlorides are not as facile to undergo oxidative addition to Pd
catalysts as aryl bromides or iodides, especially electron-rich systems, see:
Littke, A. F.; Fu, G. C. Angew. Chem., Int. Ed. 2002, 41, 4176.
(6) Bright, G. M.; Brodney, M. A.; Wlodecki, U.S. Patent 7,345,038
B2, 2008; Chem. Abstr. 2004, 141, 296048.
(7) For experimental procedures on the route leading up to 4, see:
(a) Urban, F. J. U.S. Patent 5,719,286 A, 1998; Chem. Abstr. 1994, 121,
108844; (b) Urban, F. J. J. Heterocycl. Chem. 1995, 32, 857. A related
route also leading to 17 has been disclosed, see: Urban, F. J.; Breiten-
bach, R.; Murtishaw, C. W.; Vanderplas, B. V. Tetrahedron: Asymmetry
1995, 6, 321.
(27) We have had experience handling 3-chlorobenzo[d]isothiazole
which is a known irritant sold by numerous suppliers and suspected that
3-hydroxybenzo[d]isoxazole may possess similar hazards in handling.
(8) For this campaign, Carbogen had prepared 11 for us.
1335
dx.doi.org/10.1021/op2001854 |Org. Process Res. Dev. 2011, 15, 1328–1335